High frequency of HER2-specific immunity observed in patients (pts) with HER2+ cancers treated with margetuximab (M), an Fc-enhanced anti-HER2 monoclonal antibody (mAb).

Jeffrey L.  Nordstrom

Employment - Macrogenics

Stock and Other Ownership Interests  - Macrogenics

John  Muth

No Relationships to Disclose

Courtney L.  Erskine

Research Funding - TapImmune Inc.

Catherine  Sanders

Employment - Adaptive Biotechnologies

Stock and Other Ownership Interests  - Adaptive Biotechnologies

Erik C.  Yusko

Employment - Adaptive Biotechnologies

Ryan O  Emerson

Employment - Adaptive Biotechnologies

Stock and Other Ownership Interests  - Adaptive Biotechnologies

Min-Jung  Lee

No Relationships to Disclose

Sunmin  Lee

No Relationships to Disclose

Jane B  Trepel

Patents, Royalties, Other Intellectual Property - National Cancer Institute (Inst)

Seock-Ah  Im

Consulting or Advisory Role - AstraZeneca; Eisai; Novartis; Pfizer; Roche/Genentech

Research Funding - AstraZeneca; Pfizer

Travel, Accommodations, Expenses - MSD Oncology; Novartis; Roche/Genentech

Other Relationship - Roche

Yung-Jue  Bang

Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Genexine; Green Cross; Hanmi; Lilly; Merck Serono; MSD Oncology; Novartis; Samyang; Taiho Pharmaceutical

Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Chong Kun Dang Pharmaceutical (Inst); Curis (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Genexine (Inst); GlaxoSmithKline (Inst); Green Cross (Inst); Lilly (Inst); Macrogenics (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)

Giuseppe  Giaccone

Consulting or Advisory Role - ARMO BioSciences; BerGenBio; G1 Therapeutics

Research Funding - Bayer; Incyte; Lilly

Todd Michael  Bauer

Employment - Tennessee Oncology

Consulting or Advisory Role - Guardant Health; Ignyta (Inst); Loxo; Moderna Therapeutics (Inst); Pfizer; Pfizer (Inst)

Speakers' Bureau - Bayer

Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Five Prime Therapeutics (Inst); Foundation Medicine (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immunocore (Inst); Immunogen (Inst); Incyte (Inst); Jacobio (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Loxo (Inst); MabVax (Inst); MedImmune (Inst); medpacto (Inst); Merck (Inst); Merrimack (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Onyx (Inst); Peleton (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); Principa Biopharma (Inst); Roche (Inst); Sanofi (Inst); Stemline Therapeutics (Inst); Takeda (Inst); Top Alliance BioScience (Inst)

Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Celgene; Clovis Oncology; EMD Serono; Genentech; Lilly; Merck; Novartis; Pharmacyclics; Sysmex

Howard A.  Burris

Employment - HCA Healthcare

Leadership - HCA Healthcare

Stock and Other Ownership Interests  - HCA Healthcare

Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); FORMA Therapeutics (Inst); Janssen (Inst); MedImmune (Inst); Mersana (Inst); Novartis (Inst); Roche/Genentech (Inst); TG Therapeutics (Inst)

Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); CicloMed (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Harpoon therapeutics (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Jiangsu Hengrui Medicine (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Millennium (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); TG Therapeutics (Inst); Valent Technologies (Inst); Verastem (Inst); Vertex (Inst)

Expert Testimony - Novartis

Jan E.  Baughman

Employment - Macrogenics

Stock and Other Ownership Interests  - Macrogenics

Edwin P.  Rock

Employment - Macrogenics

Stock and Other Ownership Interests  - Macrogenics

Paul A.  Moore

Stock and Other Ownership Interests  - GlaxoSmithKline; Medtronic; Teva

Patents, Royalties, Other Intellectual Property - Have patents based on work at MacroGenics, Human Genome Sciences and Celera

Ezio  Bonvini

Employment - MacroGenics

Leadership - MacroGenics

Stock and Other Ownership Interests  - Macrogenics

Research Funding - MacroGenics (Inst)

Patents, Royalties, Other Intellectual Property - Patent application and issued patents held by the US Federal Government (I); Patent applications and issued patents held by MGNX

Keith L  Knutson

Research Funding - TapImmune Inc. (Inst)

Patents, Royalties, Other Intellectual Property - Mayo Clinic